rss
Ann Rheum Dis 2003;62:771-774 doi:10.1136/ard.62.8.771
  • Concise report

Antiphospholipid antibody in localised scleroderma

  1. S Sato1,
  2. M Fujimoto2,
  3. M Hasegawa1,
  4. K Takehara1
  1. 1Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
  2. 2Department of Regenerative Medicine, Research Institute, International Medical Centre of Japan, Tokyo, Japan
  1. Correspondence to:
    Dr S Sato, Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan;
    s-sato{at}med.kanazawa-u.ac.jp
  • Accepted 21 January 2003

Abstract

Objective: To investigate the prevalence and clinical correlation of antiphospholipid antibodies in localised scleroderma.

Methods: Antibodies against cardiolipin (aCL) or β2-glycoprotein I were examined by enzyme linked immunosorbent assay (ELISA) in 48 patients with localised scleroderma (18 patients with generalised morphoea, 20 with linear scleroderma, and 10 with morphoea). Twenty one of these patients were investigated for lupus anticoagulant (LAC) by screening and confirmatory coagulation tests.

Results: Patients with generalised morphoea, the severest form of localised scleroderma, had significantly raised levels of IgM or IgG aCL relative to normal controls (n=21) and patients with systemic sclerosis (n=20). The IgM isotype was predominant, with the frequency of IgM aCL (61%) higher than that of IgG aCL (28%). Levels of aCL were similar for patients with linear scleroderma or morphoea and normal controls. IgM aCL were associated with a greater number of lesions, especially plaque lesions, wider distribution of lesions, and the presence of immunological abnormalities including antinuclear antibodies, rheumatoid factor, IgM antihistone antibodies, IgG anti-single stranded DNA antibodies, and raised serum interleukin 6 levels in patients with localised scleroderma. LAC was detected in 5/7 (71%) patients with generalised morphoea. However, pulmonary embolism was seen in only one patient with generalised morphoea. None of patients with localised scleroderma exhibited anti-β2-glycoprotein I antibodies.

Conclusions: These results suggest that aCL and LAC are the major autoantibodies in patients with generalised morphoea.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.